239 related articles for article (PubMed ID: 26746658)
1. The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.
Redelfs L; Fischer J; Weber C; Wu Z; Meyer-Hoffert U
Arch Dermatol Res; 2016 Mar; 308(2):133-7. PubMed ID: 26746658
[TBL] [Abstract][Full Text] [Related]
2. SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.
Brattsand M; Stefansson K; Hubiche T; Nilsson SK; Egelrud T
J Invest Dermatol; 2009 Jul; 129(7):1656-65. PubMed ID: 19194479
[TBL] [Abstract][Full Text] [Related]
3. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SPINK9, a KLK5-specific inhibitor expressed in palmo-plantar epidermis.
Brännström K; Ohman A; von Pawel Rammingen U; Olofsson A; Brattsand M
Biol Chem; 2012 Apr; 393(5):369-77. PubMed ID: 22505519
[TBL] [Abstract][Full Text] [Related]
5. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
[TBL] [Abstract][Full Text] [Related]
6. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases.
Meyer-Hoffert U; Wu Z; Kantyka T; Fischer J; Latendorf T; Hansmann B; Bartels J; He Y; Gläser R; Schröder JM
J Biol Chem; 2010 Oct; 285(42):32174-81. PubMed ID: 20667819
[TBL] [Abstract][Full Text] [Related]
7. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
8. Cross-linking of SPINK6 by transglutaminases protects from epidermal proteases.
Fischer J; Koblyakova Y; Latendorf T; Wu Z; Meyer-Hoffert U
J Invest Dermatol; 2013 May; 133(5):1170-7. PubMed ID: 23303447
[TBL] [Abstract][Full Text] [Related]
9. SPINK9 stimulates metalloprotease/EGFR-dependent keratinocyte migration via purinergic receptor activation.
Sperrhacke M; Fischer J; Wu Z; Klünder S; Sedlacek R; Schroeder JM; Meyer-Hoffert U; Reiss K
J Invest Dermatol; 2014 Jun; 134(6):1645-1654. PubMed ID: 24441102
[TBL] [Abstract][Full Text] [Related]
10. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides.
Komatsu N; Takata M; Otsuki N; Ohka R; Amano O; Takehara K; Saijoh K
J Invest Dermatol; 2002 Mar; 118(3):436-43. PubMed ID: 11874482
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
Fischer J; Wu Z; Kantyka T; Sperrhacke M; Dimitrieva O; Koblyakova Y; Ahrens K; Graumann N; Baurecht H; Reiss K; Schröder JM; Proksch E; Meyer-Hoffert U
J Invest Dermatol; 2014 May; 134(5):1305-1312. PubMed ID: 24352040
[TBL] [Abstract][Full Text] [Related]
12. The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases.
Karagece Yalçin U; Seçkın S
Turk Patoloji Derg; 2012; 28(2):119-27. PubMed ID: 22627629
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
[TBL] [Abstract][Full Text] [Related]
14. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.
Komatsu N; Takata M; Otsuki N; Toyama T; Ohka R; Takehara K; Saijoh K
J Invest Dermatol; 2003 Sep; 121(3):542-9. PubMed ID: 12925213
[TBL] [Abstract][Full Text] [Related]
15. Incomplete KLK7 Secretion and Upregulated LEKTI Expression Underlie Hyperkeratotic Stratum Corneum in Atopic Dermatitis.
Igawa S; Kishibe M; Minami-Hori M; Honma M; Tsujimura H; Ishikawa J; Fujimura T; Murakami M; Ishida-Yamamoto A
J Invest Dermatol; 2017 Feb; 137(2):449-456. PubMed ID: 27769847
[TBL] [Abstract][Full Text] [Related]
16. Attenuated kallikrein-related peptidase activity disrupts desquamation and leads to stratum corneum thickening in human skin equivalent models.
McGovern JA; Meinert C; de Veer SJ; Hollier BG; Parker TJ; Upton Z
Br J Dermatol; 2017 Jan; 176(1):145-158. PubMed ID: 27442805
[TBL] [Abstract][Full Text] [Related]
17. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.
Nin M; Katoh N; Kokura S; Handa O; Yoshikawa T; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):17-24. PubMed ID: 19118981
[TBL] [Abstract][Full Text] [Related]
18. Squamous cell carcinoma arising in lichen simplex chronicus.
Wu M; Wang Y; Bu W; Jia G; Fang F; Zhao L
Eur J Dermatol; 2010; 20(6):858-9. PubMed ID: 20959279
[No Abstract] [Full Text] [Related]
19. Clinical features of actinic keratoses and early squamous cell carcinoma.
Wheller L; Soyer HP
Curr Probl Dermatol; 2015; 46():58-63. PubMed ID: 25561207
[TBL] [Abstract][Full Text] [Related]
20. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
Deraison C; Bonnart C; Lopez F; Besson C; Robinson R; Jayakumar A; Wagberg F; Brattsand M; Hachem JP; Leonardsson G; Hovnanian A
Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
